Literature DB >> 23421859

From "Special K" to "Special M": the evolution of the recreational use of ketamine and methoxetamine.

Ornella Corazza1, Sulaf Assi, Fabrizio Schifano.   

Abstract

This article reviews the recreational use of ketamine ("Special K"; KET) and explores the recent diffusion of its new derivative methoxetamine ("Special M"; MXE). The literature search on the nonclinical/recreational use of KET and MXE was carried out in a range of medical databases. Considering the limitations of peer-reviewed information, data were integrated with a qualitative assessment of a range of websites, drug fora, and other online resources including e-newsgroups, chat rooms, mailing lists, e-newsletters, and bulletin boards. The recreational use of KET has started since its discovery in 1962. This was due to its rapid onset, short duration of action, and peculiar psychotropic effects ("K-hole"). The latter effect ranges from confusion to dissociation and depersonalization (near-death experience). However, KET abuse is often associated with physical and psychological side effects, of which the worst is urological/bladder toxicity. Recently, MXE has emerged as a legal and "bladder-friendly" KET alternative. MXE presents with the same dissociative effect of KET, but with slower onset and longer duration of action. However, MXE seems to be associated with worse side effects than KET, ranging from mood disturbances/suicidal attempts to acute cerebellar toxicity. After 50 years of its discovery, KET has led to the emergence of MXE. However, this latter derivative does not appear to be a safer alternative to KET itself.
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23421859      PMCID: PMC6493581          DOI: 10.1111/cns.12063

Source DB:  PubMed          Journal:  CNS Neurosci Ther        ISSN: 1755-5930            Impact factor:   5.243


  24 in total

1.  Bladder leiomyosarcoma in a patient with chronic ketamine abuse: A case report.

Authors:  Dewen Zhong; Feng Yu; Jiande Chen; Chaolu Lin; Huaijing Luo
Journal:  Can Urol Assoc J       Date:  2015 Jul-Aug       Impact factor: 1.862

2.  Methoxetamine affects brain processing involved in emotional response in rats.

Authors:  M T Zanda; P Fadda; S Antinori; M Di Chio; W Fratta; C Chiamulera; L Fattore
Journal:  Br J Pharmacol       Date:  2017-08-19       Impact factor: 8.739

3.  The novel ketamine analog methoxetamine produces dissociative-like behavioral effects in rodents.

Authors:  Adam L Halberstadt; Natalia Slepak; James Hyun; Mahalah R Buell; Susan B Powell
Journal:  Psychopharmacology (Berl)       Date:  2016-01-13       Impact factor: 4.530

Review 4.  Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.

Authors:  Panos Zanos; Ruin Moaddel; Patrick J Morris; Lace M Riggs; Jaclyn N Highland; Polymnia Georgiou; Edna F R Pereira; Edson X Albuquerque; Craig J Thomas; Carlos A Zarate; Todd D Gould
Journal:  Pharmacol Rev       Date:  2018-07       Impact factor: 25.468

Review 5.  Clinical applications of hallucinogens: A review.

Authors:  Albert Garcia-Romeu; Brennan Kersgaard; Peter H Addy
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

6.  Primary cilia safeguard cortical neurons in neonatal mouse forebrain from environmental stress-induced dendritic degeneration.

Authors:  Seiji Ishii; Toru Sasaki; Shahid Mohammad; Hye Hwang; Edwin Tomy; Fahad Somaa; Nobuyuki Ishibashi; Hideyuki Okano; Pasko Rakic; Kazue Hashimoto-Torii; Masaaki Torii
Journal:  Proc Natl Acad Sci U S A       Date:  2020-12-21       Impact factor: 11.205

7.  Memantine and Ketamine Differentially Alter NMDA Receptor Desensitization.

Authors:  Nathan G Glasgow; Nadezhda V Povysheva; Andrea M Azofeifa; Jon W Johnson
Journal:  J Neurosci       Date:  2017-09-06       Impact factor: 6.167

Review 8.  Recent insights into the mode of action of memantine and ketamine.

Authors:  Jon W Johnson; Nathan G Glasgow; Nadezhda V Povysheva
Journal:  Curr Opin Pharmacol       Date:  2014-12-02       Impact factor: 5.547

9.  The ketamine-like compound methoxetamine substitutes for ketamine in the self-administration paradigm and enhances mesolimbic dopaminergic transmission.

Authors:  Anna Mutti; Sonia Aroni; Paola Fadda; Laura Padovani; Laura Mancini; Roberto Collu; Anna Lisa Muntoni; Liana Fattore; Cristiano Chiamulera
Journal:  Psychopharmacology (Berl)       Date:  2016-03-28       Impact factor: 4.530

Review 10.  Nephrotoxic effects of designer drugs: synthetic is not better!

Authors:  Randy L Luciano; Mark A Perazella
Journal:  Nat Rev Nephrol       Date:  2014-03-25       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.